Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of pcos.

Who Took Part

According to the abstract, 23 women were involved.

The age groups tagged for this paper are teenagers, young adults and adults, women only.

Sixty-eight VD-deficient women with PCOS who were not pregnant or taking any exogenous hormones were recruited between October 2013 and January 2015.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

This was a prospective, randomized, placebo-controlled trial.

The study was conducted at an academic-affiliated medical center.

What Was Measured

Topics PubMed links to this paper include Antigens, CD, Biological Availability, Cholecalciferol, Dehydroepiandrosterone Sulfate, Endoglin, Insulin Resistance and Lipids.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 23 women in people with pcos.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, PCOS research.